Venlafaxine
75 mg · Tablet, Extended Release
- Prescription only
- Serotonin and Norepinephrine Reuptake Inhibitor
- Active substance
- Venlafaxine
- Made by
- Zydus Lifesciences Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
This information is not included in the verified source. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Venlafaxine Hydrochloride). It describes the substance, not this exact product.
The mechanism of the antidepressant action of venlafaxine in humans is believed to be associated with its potentiation of neurotransmitter activity in the CNS.
Preclinical studies have shown that venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake.
Absorption and Distribution Venlafaxine is well absorbed and extensively metabolized in the liver.
Food did not affect the pharmacokinetic parameters AUC, C max, and T max of venlafaxine or its active metabolite, ODV, after administration of venlafaxine extended-release tablets.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-27
Safety of the active substance
From the US prescribing label for the same active substance (Venlafaxine Hydrochloride). It describes the substance, not this exact product.
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.
- Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with venlafaxine extended-release tablets or within 7 days of stopping treatment with venlafaxine extended-release tablets.
- Do not use venlafaxine extended-release tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders.
- In addition, do not start venlafaxine extended-release tablets in a patient who is being treated with linezolid or intravenous methylene blue.
- ( 4.1 ) 4.1 Monoamine Oxidase Inhibitors (MAOIs) The use of MAOI’s intended to treat psychiatric disorders with venlafaxineextended-release tablets or within 7 days of stopping treatment with venlafaxineextended-release tablets is contraindicated because of an increased risk of serotonin syndrome.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Details
| Made by | Zydus Lifesciences Limited |
|---|---|
| Active substance | Venlafaxine |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 75 mg |
| Form | Tablet, Extended Release |
| Route | Oral |
| Packs | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE |
| NDC | 70771-1650 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
106 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Tablet79 products
- Tablet, Extended Release21 products
37.5 mg4
75 mg5
75 mg · 5 companies
- Ajanta Pharma USA Inc.
- Ascend Laboratories, LLC
- REMEDYREPACK INC.
- Zydus Lifesciences Limited · this page
- Zydus Pharmaceuticals USA Inc.
- 112.5 mg
- Tablet, Coated6 products
75 mg2
75 mg · 2 companies
150 mg2
150 mg · 2 companies
225 mg2
225 mg · 2 companies
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.